Breaking Down Tasly Pharmaceutical Group Co., Ltd Financial Health: Key Insights for Investors

Curious whether Tasly Pharmaceutical Group Co., Ltd. (600535.SS) is a buy, hold or watch? The numbers tell a nuanced story: in H1 2025 revenue was approximately CNY 4.29 billion with TTM revenue of CNY 8.35 billion (both slightly down year-over-year), yet net profit attributable to shareholders jumped nearly 17% to CNY 774.7 million and the company posts a robust net profit margin of 18%, while balance-sheet metrics show conservative leverage with a debt-to-equity ratio of 0.07; complementary signals include a market cap near CNY 22.7-22.8 billion, EPS (TTM) of CNY 0.74, P/E (TTM) 20.54 and forward P/E 13.04, strong liquidity (current ratio 3.82, quick ratio 3.07, net cash CNY 2.63 billion), high gross margin (67.08%) and solid cash generation (operating cash flow CNY 1.70 billion, free cash flow CNY 1.24 billion), set against industry risks such as regulatory change, input-cost and competitive pressures-read on for a chapter-by-chapter breakdown that dives deep into revenue drivers, profitability levers, capital structure, valuation angles and the growth opportunities and risks that matter to investors.

Tasly Pharmaceutical Group Co., Ltd (600535.SS) Revenue Analysis

Tasly Pharmaceutical Group reported mixed top-line performance through 2024-2025 with modest declines in both year-over-year and trailing periods, while maintaining solid operational scale and market valuation metrics that investors should weigh alongside growth drivers and margin dynamics.

• H1 2025 revenue: CNY 4.29 billion (down 1.91% YoY)
• TTM revenue as of 30 Sep 2025: CNY 8.35 billion (down 2.56% vs. TTM 2024)
• FY 2024 revenue: CNY 8.50 billion (down 2.03% from CNY 8.67 billion in FY 2023)
• Revenue per employee: ~CNY 761,660 (10,958 employees)
• Market capitalization: CNY 22.81 billion; P/S ratio: 2.73
• 52-week price range: CNY 13.51 - CNY 17.69

Key implications for investors include revenue stability at large scale, modest contraction over recent periods, and valuation that implies expectations of either recovery or improved margins. For further context on ownership and investor behavior, see: Exploring Tasly Pharmaceutical Group Co., Ltd Investor Profile: Who's Buying and Why?

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Profitability Metrics

Key profitability indicators for Tasly Pharmaceutical Group Co., Ltd (600535.SS) through the most recent reporting period signal improved earnings quality and operational efficiency across core business lines. The first half of 2025 shows notable year-on-year improvement in net profit and sustained strong gross margins driven by product mix and cost control.

• Net profit attributable to shareholders (1H 2025): CNY 774.7 million - an increase of nearly 17% year-on-year.
• Net profit margin (trailing period): ~18%.
• Return on equity (ROE): 8.02%.
• Return on assets (ROA): 5.01%.
• Gross profit: CNY 5.60 billion; Gross margin: 67.08%.
• Operating margin: 15.25%; Profit margin: 13.15%.
• Earnings per share (trailing twelve months): CNY 0.74; Price-to-earnings (P/E) ratio: 20.54.

For further context on Tasly's business model, ownership and historical performance, see: Tasly Pharmaceutical Group Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Debt vs. Equity Structure

• Total liabilities: CNY 2.85-2.87 billion (mid-2025).
• Total assets: > CNY 14-15 billion (mid-2025).
• Equity (book value): CNY 12.50 billion; book value per share: CNY 8.24.
• Net cash position: CNY 2.63 billion (CNY 1.76 per share).
• Debt-to-equity ratio: 0.07.
• Interest coverage ratio: 45.27.
• Enterprise value / EBITDA: 12.09.

• Low leverage: With liabilities under CNY 3 billion against over CNY 14 billion in assets and equity of CNY 12.50 billion, balance-sheet risk from debt is minimal.
• Strong interest coverage: A ratio of 45.27 indicates operating earnings comfortably cover interest expense, reducing refinancing risk.
• High net cash: CNY 2.63 billion in net cash (CNY 1.76 per share) provides flexibility for R&D investment, M&A, dividends or buybacks without recourse to heavy debt.
• Valuation context: EV/EBITDA of 12.09 situates the company at a moderate multiple relative to earnings-useful when comparing peers or assessing acquisition premium scenarios.

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Liquidity and Solvency

• Current ratio: 3.82 - strong short-term liquidity, showing ample current assets relative to current liabilities.
• Quick ratio: 3.07 - indicates sufficient ability to meet short-term obligations without relying on inventory.
• Net cash position: CNY 2.63 billion - a positive cash buffer to absorb shocks or fund opportunities.
• Altman Z-Score: 7.89 - well above distress thresholds, implying low bankruptcy risk.
• Piotroski F-Score: 8 - signals robust fundamental financial health across profitability, leverage/liquidity, and operating efficiency metrics.
• Operating cash flow: CNY 1.70 billion; Free cash flow: CNY 1.24 billion - strong cash generation and retained cash after capital expenditures.

• Investor considerations: with a robust current and quick ratio, a strong net cash balance, high Altman Z-Score and Piotroski F-Score, plus solid operating and free cash flows, Tasly's balance sheet is positioned to withstand near-term liquidity pressures and pursue strategic opportunities.
• Watchpoints: monitor changes in working capital, capex requirements, and any material shift in cash position or leverage that could affect these metrics over time.

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Valuation Analysis

• Trailing P/E: 20.54 - current-year earnings multiple.
• Forward P/E: 13.04 - implied cheaper valuation on projected earnings.
• P/S: 2.72 - moderate premium to sales.
• P/B: 1.82 - trading below 2x book value, suggesting balance-sheet support.
• PEG: 1.09 - valuation roughly in line with expected earnings growth (near 1.0).
• EV/EBITDA: 12.09 - enterprise-level valuation vs. operating cash profitability.
• Market Capitalization: CNY 22.69 billion; Enterprise Value: CNY 20.26 billion - EV slightly below market cap, reflecting net cash or minority adjustments.

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Risk Factors

• Regulatory risk: The pharmaceutical sector faces frequent and stringent regulatory changes (drug approvals, GMP inspections, pricing reforms). Delays or non-compliance can materially affect product launches and revenue timing.
• Raw material cost volatility: Active pharmaceutical ingredient (API) and excipient price swings can compress gross margins, especially for volume-sensitive generics and traditional medicine inputs.
• Competition: Intense domestic and global competition from large pharma, generics manufacturers and biotech startups may pressure market share and pricing.
• Currency exposure: Revenues from export markets and cross‑border procurement expose earnings to RMB/USD and other FX volatility.
• Intellectual property and legal risk: Patent disputes, data exclusivity challenges or litigation around formulations and processes may impose costs or restrict sales.
• Macro/economic sensitivity: Economic downturns or constrained public healthcare budgets can reduce demand for non-essential therapies and slow hospital procurement cycles.

• Regulatory-change scenarios: A 6-12 month delay in a key product approval could reduce near-term revenues by an estimated 5-8% depending on market substitution and hospital procurement cycles.
• Raw material shock: A 25% increase in key API prices could cut gross margin by ~3-6 percentage points, assuming limited ability to pass costs to payers.
• Competitive pricing pressure: Pricing competition in generics and Traditional Chinese Medicine (TCM) formulations could erode market share by mid-single digits over 2-3 years without new product differentiation.
• FX impact example: A 10% RMB depreciation against USD could increase RMB-reported export revenue by ~2% of total revenue while raising import costs for certain APIs (net effect dependent on hedging).
• Legal/IP risk: Major IP litigation could trigger one-time charges (tens to hundreds of millions RMB) and injunctions limiting sales of affected products.
• Macro scenario: A 1% contraction in domestic healthcare spending could reduce Tasly's hospital sales growth by 1-3 percentage points in the near term, with larger impacts on elective or non-reimbursed products.

• Key monitoring indicators for investors:
  • Regulatory milestones and approval timelines for pipeline products
  • API price trends and supplier concentration
  • R&D pipeline progress and patent filings
  • FX hedging disclosures and export revenue mix
  • Receivables turnover and inventory days (working capital strain)

Tasly Pharmaceutical Group Co., Ltd (600535.SS) - Growth Opportunities

• Expansion into emerging markets: targeting Southeast Asia, MENA and selected African markets where traditional medicine and chronic-disease therapeutics are growing; addressable market estimates for these regions exceed CNY 150-300 billion in relevant therapy areas.
• Increased R&D investment: lifting R&D to ~6-8% of revenue could accelerate new innovative product launches in cardiovascular and metabolic indications where Tasly has existing pipelines.
• Strategic partnerships and acquisitions: bolt-on deals focusing on biologics, high-value generics, or complementary TCM (traditional Chinese medicine) capabilities can fill capability gaps and accelerate market entry.
• OTC diversification: expanding branded over‑the‑counter portfolio and consumer healthcare channels to capture higher-margin, less-regulated sales volumes.
• Digital health adoption: remote patient monitoring, telemedicine partnerships and digital adherence tools to improve outcomes and create subscription-like revenue streams.
• Strengthening sales & distribution: expanding provincial-level distributors, e-commerce channels and hospital access programs to increase penetration in second- and third-tier cities.

• Prioritization: focus first on R&D scale-up and distribution strengthening to maximize ROI within 24 months.
• Capital allocation: allocate incremental EBIT to a mix of R&D (40%), M&A (30%), and digital/OTC commercialization (30%).
• KPIs to monitor: revenue by segment, gross margin, R&D pipeline milestones (IND/NDA), international sales CAGR, digital engagement metrics, and M&A integration ROIC.